LEARN MORE Our mission is to ensure every patient around the world has access to affordable, high-quality monoclonal antibody (mAb) biosimilar therapeutics.
BioXpress develops cost-competitive biosimilar mAb biologics with the highest safety and quality standards.
BioXpress Therapeutics SA is a premier partner for high-quality biosimilar monoclonal antibodies for unmet need indications such as cancer, inflammation and autoimmunity, including adaptive immunity. We have made a commitment to be your partner of choice for the full development of your biosimilar biologic. BioXpress Therapeutics is focused on developing the highest quality product under strict European Medicines Agency (EMA) guidelines. We bring together the world’s top biologic development, manufacturing and regulatory experts dedicated to your project.
Each BioXpress monoclonal antibody biosimilar is developed under strict non-clinical and clinical guidelines as outlined in the European Medicines Agency’s (EMA) “Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies.”
ACCESS TO AFFORDABLE BIOLOGICS
BioXpress is committed to operating in ways that enhance society and the environment.
CORPORATE AND SOCIAL RESPONSIBILITY
BioXpress is committed to developing biosimilar mAbs in ways that enhance society while reducing environmental impact.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.